MMRF Honored for Fifteenth Year for Outstanding Stewardship of Donors’ Funds
June 14, Norwalk, Connecticut. The Multiple Myeloma Research Foundation (MMRF) received a 4-star rating from Charity Navigator, America’s largest independent evaluator of charitable donations, for demonstrating strong financial health and commitment to accountability and transparency. This is the fifteenth time the MMRF has earned this coveted recognition.
The coveted 4-star rating, the highest honor Charity Navigator bestows, indicates that “The Multiple Myeloma Research Foundation exceeds industry standards and outperforms most charities.” According to Charity Navigator, “this sets the MMRF apart from its peers and demonstrates to the public its trustworthiness.”
“Charity Navigator’s 4-star rating underscores our tireless commitment to accountability, efficiency and measurable results” said Paul Giusti, CEO of the MMRF. “Our commitment to our patients and donors remains focused on maximizing every dollar we invest.”
About the Multiple Myeloma Research Foundation (MMRF)
The mission of the Multiple Myeloma Research Foundation (MMRF) is to find a cure for multiple myeloma by relentlessly pursuing innovation that accelerates the development of next-generation treatments to extend the lives of patients. Founded in 1998 by Kathy Giusti, a multiple myeloma patient, and her twin sister Karen Andrews as a 501(c) (3) nonprofit organization, the MMRF is a world-recognized leader in cancer research. Together with its partners, the MMRF has created the only end-to-end solution in precision medicine and the single largest genomic dataset in all cancers. The MMRF continues to disrupt the industry today, as a pioneer and leader at the helm of new research efforts. Since its inception, the organization has raised over $400 million and directs nearly 90% of the total funds to research and related programs. To learn more, visit www.themmrf.org.
Benefits Outweigh Risks as FDA Inspects CAR-T Cell Therapy-Related Cancer
November 29th 2023The FDA announced rare instances of secondary diseases or cancers from CAR-T cell therapy, though this is not the first time that oncology treatments have been associated with secondary diseases.
Read More
Patrick Dempsey Reflects on His Nonprofit, ‘General Hospital’ Star Talks Cancer and More
November 10th 2023From actor Patrick Dempsey saying that his late mother would be proud of his work at The Dempsey Center to a “General Hospital” actor discussing his cancer treatments, here’s what’s happening in the oncology space this week.
Read More
Benefits Outweigh Risks as FDA Inspects CAR-T Cell Therapy-Related Cancer
November 29th 2023The FDA announced rare instances of secondary diseases or cancers from CAR-T cell therapy, though this is not the first time that oncology treatments have been associated with secondary diseases.
Read More
Patrick Dempsey Reflects on His Nonprofit, ‘General Hospital’ Star Talks Cancer and More
November 10th 2023From actor Patrick Dempsey saying that his late mother would be proud of his work at The Dempsey Center to a “General Hospital” actor discussing his cancer treatments, here’s what’s happening in the oncology space this week.
Read More
2 Clarke Drive
Cranbury, NJ 08512